Levobetaxolol

Levobetaxolol

File:Levobetaxolol-fill.png
File:Levobetaxolol.png
Gene therapy
Clinical data
Routes of administration	topical (opthalmic)
Physiological data
Legal status
Pharmacokinetic data
Elimination half-life	20 hours
Identifiers
IUPAC name (S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride
CAS Number	93221-48-8
PubChem Template:Abbreviation	60657
Chemical and physical data
Formula	C18H29NO3
Molar mass	342.472 g/mol

Levobetaxolol or Levobetxolol hydrochloride is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is typically marketed as a 0.5% opthalmic solution under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker.

Effect

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It is indicated for IOP reduction in patients with open-angle glaucoma or ocular hypertension. Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure.

The drug has been associated with bradycardia and hypertension.